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ABSTRACT 
Background: Autologous stem cell transplantation is considered a standard of care treatment in eligible 
patients with multiple myeloma, but puts the patient at high risk for infections and bleeding complications. 
Acquired von-Willebrand's disease (AVWD) and acquired platelet dysfunction are rare bleeding disorders that 
are associated with lymphoproliferative disorders such as multiple myeloma. Patients with acquired bleeding 
disorders who are planned for ASCT to treat the underlying condition are considered at highest risk for 
bleeding complications, and optimal treatment strategies are not known.  
Materials and Methods: We summarized the diagnostic and therapeutic approach to a patient affected by 
AVWD and acquired platelet disorder related to multiple myeloma. The patient who was planned for ASCT 
presented with moderate to severe bleeding symptoms.  
Results: Acute bleeding episodes were successfully controlled and prevented during induction and 
consolidation therapy with immunoglobulins, whereas replacement of plasma-derived VW factor showed no 
clinical improvement. High-dose melphalan-based consolidation therapy supported with autologous stem-cell 
transplantation led to an immediate and sustainable rise of von-Willebrand antigen and activity and a 
subsequent normalization of platelet aggregation activity. After a follow-up of 40 weeks, the patient 
maintained normalized VW levels and platelet aggregation capacity. There were no further signs or symptoms 
of bleeding.  
Conclusion: This case report highlights the necessity for combined supportive and causal treatment in 
patients with AVWD and paraproteinemic PD. High-dose melphalan with autologous stem cell support may 
function as a treatment option in patients with myeloma-related AVWD.  
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INTRODUCTION 
  Multiple myeloma (MM) is a malignant plasma-cell 
disorder whose clinical features include lytic bone 
lesions, anemia, kidney failure and hypercalcemia. 
The initial therapy of symptomatic MM varies 
depending on risk stratification and fitness of the 
patient; however, international guidelines 
recommend high-dose chemotherapy followed by 
autologous stem cell transplantation (ASCT) in 
eligible patients to improve survival1. Patients who 
undergo ASCT are at high risk for infections and 
bleeding complications due to transient severe 
pancytopenia and prophylactic measures, including 
the use of broad spectrum antibiotics and 
transfusion of platelet and blood products2,3.   
Acquired von-Willebrand disease (AVWD) and 
acquired platelet dysfunction (APD) are rare 
bleeding disorders that are associated with 
lymphoproliferative disorders such as MM. Clinical 
features involve mucocutaneous bleeding, 
menorrhagia and prolonged bleeding from minor 
bruises or dental procedures, thus resembling the 
inherited VWD and inherited PD in clinical findings 4.  
Patients with acquired bleeding disorders who are 
planned for ASCT to treat the underlying condition 
are considered at high risk for bleeding 
complications. Optimal treatment strategies have 
not been established due to the limited number of 
affected patients and multiple pathophysiologic 
mechanisms of these acquired bleeding disorders5. 
In general, causal treatment of the underlying 
condition is considered crucial for sustainable 
response and supportive treatment (such as the 
administration of desmopressin, replacement of 
VWF, immunoglobulins, plasmapheresis and 
antifibrinolytics) aiming to control and prevent 
severe bleeding episodes6. 
In the following case report, we describe a patient 
affected by AVWD and APD related to MM. We 
review our diagnostic workup and treatment 
approach to control acute bleeding events, prevent 
bleeding in high-risk situations and obtain long-term 
remission. Written informed consent was provided 
by the patient. 
 
 
Case presentation 
A 62-year-old male patient with MM IgG kappa, ISS 
17, anemia (10.3g/dl [normal range 13.5 – 17-5g/dl]) 
and two isolated bone lesions in the spine was 
referred to the cancer center for treatment 
initiation (laboratory findings [standard values in 
parentheses]: β2-microglobulin, 3.2mg/l [0.8 – 
2.4mg/l]; M-gradient, 0.26g/dl, 4% [0g/dl, 0%]; 90% 
bone marrow infiltration with plasmatic cells [0.5 – 
3.0%]; serum free light chain ratio, 8.72 [0.26-1.65]; 
body weight: 65 kilogram).  
His medical history involved diabetes mellitus, 
atopic dermatitis and Bechterew´s disease with 
severe arthrosis of the right hip causing a 
wheelchair-dependency most time of the day. A 
noticeable bleeding history was documented: the 
patient suffered from nose bleeding since he was a 
child as well as intermittent severe gastrointestinal 
bleeding episodes due to angiodysplasia in the 
jejunum and ileum, which were controlled by local 
endoscopic interventions at accessible sites. 
However, an open appendectomy as a child and 
inguinal hernia repair two years ago were 
performed without major bleeding events. The 
family history for bleeding disorders was negative. 
There were no specific findings in the full body 
examination.  
The patient was referred to our department of 
hemostaseology for further diagnostic workup of 
the reported bleeding episodes in advance of the 
planned induction therapy for the MM. The 
coagulation tests showed VWF: Ag 12% [60 – 150%], 
VWF: Act < 4% [47,8 - 173,2%], VIII:C 13.6% [68 - 
133%], aPTT 51s [25-37sec], bleeding time 
epinephrin>220sec [84 – 160sec], bleeding time 
ADP > 227sec [68-121sec]), a reduced platelet 
aggregation induced by ristocetin of 9% [89-100%] 
and ADP of 63% [88-100%] and normal levels of 
coagulation factor IX and XIII. Multimer analysis 
revealed absence of all proportions of VWF, 
compatible with type 3 VWD. Administration of 
VWF concentrate in combination with 
antifibrinolytics was recommended in case of acute 
bleeding. Presence of an inhibiting autoantibody 
against VWF was excluded in our and a reference 
laboratory.  
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The patient was treated with four induction cycles 
of VCD (Bortezomib 1,3mg/m2 d1,4,8,11; 
Cyclophosphamid 900mg/m2 d1; Dexamethason 
40mg d1-12) 8 and one cycle of CAD 
(cyclophosphamide 1g/m2 d1; adriamycin 15g/m2 
d1-4; dexamethasone 40mg d1-4)9 for stem-cell 
mobilization, accompanied by standard of care 
supportive therapy. The patient suffered from two 
self-limiting mild bleeding events and low-grade 
polyneuropathy. A cumulative dose of 18250 units 
(95IE/kg bodyweight per day) of a plasma-derived 
FVIII/VWF combination concentrate (Haemate P) 
was administered on three consecutive days for 
continuous central-line insertion-site bleeding 
during stem cell collection. The patient achieved a 
stable disease after completion of the induction 
therapy. 
The patient was re-referred to our department in 
advance of the planned consolidation therapy for 
nose bleeding that was not manageable with local 
compression for more than 24hours. We 
administered an initial dose of 6000 units (92 
units/kg bodyweight) of Haemate P, but low 
concurrent recovery values with less than 10% 
VWF: Act three hours after VWF administration (see 
Figure 1B) indicated a rapid clearance of VWF. We 
hypothesized a MM associated AVWD and 
administered immunoglobulines (IVIg) 1g per kg 
bodyweight for four consecutive days. A rapid 
recovery of VWF and reoccurrence of all 
proportions of VW multimers could be documented 
on day 2 after one dose of 60g IVIg. In line with the 
laboratory findings, the formerly uncontrolled nose 
bleeding stopped after the first IVIg dose. 
Administration was repeated once (60g IVIg) to 
maintain normal VWF levels throughout the 
consolidation therapy (Figure 1A). Impairment of 
platelet aggregation, however, was not ameliorated 
by IVIg administration.  
 
 
Figure 1: (A) Development of coagulation factors and platelets during treatment:  VWF:Act, von Willebrand factor activity; VIII:C, factor VIII activity; IVIg, 
immunoglobulin; ASCT, d0 of consolidation therapy: autologous stem cell transplantation; (B) recovery of VWF:Ag, VWF:Act and VIII:C after administration 
of 92 units/kg bodyweight Haemate P (plasma-derived VWF / FVIII concentrate)  
 
 Consolidation was performed with high-dose 
melphalan at a dose of 200 mg per square meter of 
body-surface area supported with autologous stem 
cell transplantation (ASCT) using 2.57 x 106 CD34+ 
cells per kilogram bodyweight (melphalan 
100mg/m2 d-3, d-2; stem cell support d0)3. The 
patient suffering from neutropenic fever was 
successfully treated with antibiotics and no 
bleeding events were identified. An immediate and 
sustainable rise of VWF and FVIII after ASCT was 
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documented (Figure 1A). In addition, ristocetin-
induced thrombocyte aggregation and in-vitro 
bleeding time normalized 5 weeks after ASCT. The 
patient achieved a partial remission according to 
the international response criteria evaluated 9 
weeks after consolidation therapy10. Coagulation 
factors were normal at last follow-up, 40 weeks 
after ASCT. There were no clinical signs or 
symptoms of bleeding.  
DISCUSSION  
   To our knowledge, this is the first report on a 
long-term remission of a patient diagnosed with 
AVWD and PD as a complication of MM after 
administration of high-dose melphalan supported 
with ASCT. 
Distinguishing acquired from inherited VWD is 
challenging and anamnestic findings play a major 
role in making the diagnosis. In our case, the 
personal history including childhood bleeding 
events but negative family history was inconclusive, 
leading to the initial assumption of inherited VWD. 
In the course of disease, rapid clearance of plasma-
derived VWF gave rise to the correct diagnosis. 
Repeatedly, autoantibodies against VWF could be 
excluded. The general frequency of inhibiting 
autoantibodies in AVWD is low, and therefore does 
not provide enough sensitivity for the diagnosis of 
AVWD4.  
Treatment of AVWD is challenging and aims to 
control acute bleeding events, prevent bleeding in 
high-risk situations like chemotherapy-induced 
pancytopenia and obtain long-term remission. 
Immunoglobulins are a reasonable therapy option 
for lymphoproliferative-related AVWD, especially in 
IgG-restricted MM11. All proportions of VW 
multimers could already be detected after the first 
IVIg administration of 60g (0.92g per kg 
bodyweight), leading to a prolongation of the VWF 
half-life from less than one hour (Fig. 1B) to a few 
days (Fig. 1A).  
Long-term remissions of AVWD using 
immunomodulatory drugs (e.g. thalidomide) and 
proteasome inhibitors (e.g. bortezomib) have been 
described12,13, but time to treatment response 
ranged between weeks and months in these cases, 
providing limited usefulness in patients with high 
clinical burden of AVWD. This is however the first 
case of a long-term remission of AVWD achieved by 
high-dose melphalan supported with ASCT. A 
sustainable rise of VWF could be documented from 
day one after reconstitution with autologous stem 
cells that reached a maximum VWF activity within 2 
weeks after ASCT, a critical phase where therapy-
related thrombocytopenia causes a high risk for 
spontaneous bleeding events (Fig. 1A). Rise of VWF 
was accompanied by a significant reduction of 
paraproteinemia, albeit level of paraprotein does 
not necessarily correlate with clinical AVWD 
severity or laboratory findings14.  
Of interest, IVIg was not able to restore platelet 
function, indicating a non-immunogenic impairment 
of ristocetin-induced platelet aggregation. In 
accordance to Djunic et al. who performed 
systematic mixing studies and showed that adding 
IVIg to the reaction mixture was not able to restore 
platelet activity in vitro15, we have provided the first 
corresponding clinical evidence that IVIg fails to 
significantly change platelet aggregation capacity in 
paraproteinemic impairment. Platelet function and 
in-vitro bleeding time however subsequently 
normalized after high-dose melphalan therapy, 
presumably due to the general reduction of 
paraprotein burden. 
In summary, this case report highlights the 
necessity for close anamnestic review of the 
patient´s history as well as the need for combined 
supportive and causal treatment in patients with 
AVWD and paraproteinemic APD. Close monitoring 
and an interdisciplinary approach involving 
hematologists and hemostaseologists are of great 
importance to manage patients with these rare 
acquired bleeding disorders. Immunoglobulins 
provide short-term usefulness to bridge patients 
who are at high-risk for bleeding complications. 
High-dose chemotherapy followed by ASCT can be 
considered as a salvage treatment option for 
patients suffering from these rare bleeding 
disorders.  
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